stoxline Quote Chart Rank Option Currency Glossary
  
BG Medicine, Inc. (BGMD)
1.0E-6  -0 (-99%)    11-22 09:33
Open: 1.0E-6
High: 1.0E-6
Volume: 10,000
  
Pre. Close: 0.0001
Low: 1.0E-6
Market Cap: 0(M)
Technical analysis
Short term     
Mid term     
Targets 6-month :  1-year : 
Resists First :  Second : 
Pivot price
Supports First :  Second : 
MAs MA(5) :  MA(20) : 
MA(100) :  MA(250) : 
MACD MACD :  Signal : 
%K %D K(14,3) :  D(3) : 
RSI RSI(14):
52-week High :  Low : 
Price, MAs and Bollinger Bands


Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Headline News

Thu, 03 Jan 2013
BG Medicine (OTC:BGMD) rockets 24% after saying it has received the EU's CE mark for the first... (OTCMKTS:BGMD) - Seeking Alpha

Tue, 10 Jan 2012
BG Medicine puts a new man in the corner office | Personnel Moves - Mass Device

Thu, 28 Mar 2024

Thu, 28 Mar 2024

Thu, 28 Mar 2024

Thu, 28 Mar 2024

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
PNK
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders (%)
Held by Institutions (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin %
Operating Margin %
Return on Assets (ttm) %
Return on Equity (ttm) %
Qtrly Rev. Growth %
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend
Forward Dividend
Dividend Yield 0%
Dividend Pay Date
Ex-Dividend Date

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android